BLRX

BioLineRx Ltd.

Price Chart

Latest Quote

$3.13

+0.09 (+3.02%)

Current Price

Previous Close	$3.04
Open	$3.32
Day High	$3.32
Day Low	$3.09
Volume	6,448

Fetched: 2026-06-18T16:04:23

Stock Information

Shares Outstanding	4.35M
Total Debt	$9.07M
Cash Equivalents	$17.35M
Revenue	$1.40M
Net Income	$-7.90M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$14.08M
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$9.15M
Sales	$1.40M
Income	$-7.90M
Book/sh	$3.60
Cash/sh	$3.99
Employees	20

Financial Ratios

Quick Ratio	1.41
Current Ratio	1.58
Debt/Eq	43.53

Returns & Margins

ROA	-16.55%
ROE	-46.72%
Gross Margin	79.24%
Operating Margin	-629.77%

Ownership

Insider Ownership	3.91%
Institutional Ownership	0.45%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-4.89
P/S	10.05
P/B	0.87

Analyst Data

Recommendation	none
Target Price	$17.50

Technical Indicators

SMA20	$3.28
SMA50	$2.92
SMA200	$3.13
RSI	29.56
ATR	0.2336

Shares Float	4.16M
Short Float	3.83%
Short Ratio	1.55
Volatility	0.62
Rel Volume	0.19

Performance History

Week	-9.80%
Month	+19.01%
Quarter	+15.50%
6 Months	+3.99%
YTD	+11.79%
Year	-29.19%
3 Years	-95.60%
5 Years	-97.20%
10 Years	-99.38%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$3.13	6,448
2026-06-17	$3.02	12,600
2026-06-16	$3.05	11,200
2026-06-15	$3.25	20,000
2026-06-12	$3.37	51,300
2026-06-11	$3.47	5,800
2026-06-10	$3.28	4,900
2026-06-09	$3.21	8,300
2026-06-08	$3.25	13,300
2026-06-05	$3.23	6,700
2026-06-04	$3.36	20,900
2026-06-03	$3.28	20,000
2026-06-02	$3.39	22,300
2026-06-01	$3.48	51,000
2026-05-29	$3.78	106,800
2026-05-28	$3.59	95,500
2026-05-27	$3.37	96,300
2026-05-26	$3.16	62,300
2026-05-22	$3.06	55,200
2026-05-21	$2.86	9,100
2026-05-20	$2.75	62,300
2026-05-19	$2.63	1,482,600
2026-05-18	$2.80	27,600

About BioLineRx Ltd.

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

📰 Latest News

BioLine Rx Ltd (BLRX) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...

GuruFocus.com • 2026-06-03T01:01:43Z

BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX)

InvestorsHub • 2026-05-27T11:53:29Z

BioLine Rx Ltd (BLRX) Full Year 2025 Earnings Call Highlights: Navigating Challenges and ...

GuruFocus.com • 2026-03-26T01:01:14Z

BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

GuruFocus.com • 2025-11-29T01:00:21Z

H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025

Insider Monkey • 2025-07-03T02:04:18Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$230,000	$5,538,000	$2,659,000	$0
Cost Of Revenue	$230,000	$9,263,000	$3,692,000	$0
Total Revenue	$1,180,000	$28,940,000	$4,800,000	$0
Operating Revenue	$1,180,000	$28,940,000	$4,800,000	$0
Expenses
Interest Expense	$1,251,000	$9,074,000	$2,144,000	$1,786,000
Total Expenses	$11,467,000	$48,092,000	$47,791,000	$29,157,000
Other Income Expense	$8,417,000	$17,230,000	$-17,461,000	$5,324,000
Other Non Operating Income Expenses	$-522,000	$-530,000	$235,000	$-755,000
Net Non Operating Interest Income Expense	$-156,000	$-7,299,000	$-162,000	$-1,118,000
Total Other Finance Cost	$29,000	$45,000	$25,000	$26,000
Interest Expense Non Operating	$1,251,000	$9,074,000	$2,144,000	$1,786,000
Operating Expense	$11,237,000	$38,829,000	$44,099,000	$29,157,000
Selling And Marketing Expense	$0	$10,080,000	$14,592,000	$4,882,000
General And Administrative Expense	$3,916,000	$18,460,000	$16,637,000	$6,607,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-1,175,000	$-9,221,000	$-60,614,000	$-24,951,000
Net Interest Income	$-156,000	$-7,299,000	$-162,000	$-1,118,000
Interest Income	$1,124,000	$1,820,000	$2,007,000	$694,000
Normalized Income	$-10,114,000	$-26,981,000	$-42,918,000	$-31,030,000
Net Income From Continuing And Discontinued Operation	$-1,175,000	$-9,221,000	$-60,614,000	$-24,951,000
Total Operating Income As Reported	$-10,287,000	$-20,408,000	$-49,694,000	$-29,157,000
Net Income Common Stockholders	$-1,175,000	$-9,221,000	$-60,614,000	$-24,951,000
Net Income	$-1,175,000	$-9,221,000	$-60,614,000	$-24,951,000
Net Income Including Noncontrolling Interests	$-2,026,000	$-9,221,000	$-60,614,000	$-24,951,000
Net Income Continuous Operations	$-2,026,000	$-9,221,000	$-60,614,000	$-24,951,000
Pretax Income	$-2,026,000	$-9,221,000	$-60,614,000	$-24,951,000
Special Income Charges	$0	$-1,256,000	$-6,703,000	$0
Interest Income Non Operating	$1,124,000	$1,820,000	$2,007,000	$694,000
Operating Income	$-10,287,000	$-19,152,000	$-42,991,000	$-29,157,000
Depreciation Amortization Depletion Income Statement	$28,000	$340,000	$351,000	$39,000
Depreciation And Amortization In Income Statement	$28,000	$340,000	$351,000	$39,000
Depreciation Income Statement	$28,000	$340,000	$351,000	$39,000
Gross Profit	$950,000	$19,677,000	$1,108,000	$0
Per Share
Diluted EPS	$0.00	$-6.00	$-36.00	$-18.00
Basic EPS	$0.00	$-6.00	$-36.00	$-18.00
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-9,191,000	$-13,842,000	$-39,390,000	$-28,590,000
Total Unusual Items	$8,939,000	$17,760,000	$-17,696,000	$6,079,000
Total Unusual Items Excluding Goodwill	$8,939,000	$17,760,000	$-17,696,000	$6,079,000
Reconciled Depreciation	$523,000	$4,065,000	$1,384,000	$654,000
EBITDA (Bullshit earnings)	$-252,000	$3,918,000	$-57,086,000	$-22,511,000
EBIT	$-775,000	$-147,000	$-58,470,000	$-23,165,000
Diluted Average Shares	$4,108,788	$1,996,846	$1,605,609	$1,289,928
Basic Average Shares	$4,108,788	$1,996,846	$1,605,609	$1,289,928
Diluted NI Availto Com Stockholders	$-1,175,000	$-9,221,000	$-60,614,000	$-24,951,000
Minority Interests	$851,000	-	-	-
Impairment Of Capital Assets	$0	$1,010,000	$6,703,000	$0
Gain On Sale Of Security	$8,939,000	$19,016,000	$-10,993,000	$6,079,000
Provision For Doubtful Accounts	$-800,000	$800,000	$0	$0
Research And Development	$8,093,000	$9,149,000	$12,519,000	$17,629,000
Selling General And Administration	$3,916,000	$28,540,000	$31,229,000	$11,489,000
Other Gand A	$1,614,000	$2,745,000	$3,182,000	$1,901,000
Insurance And Claims	$603,000	$808,000	$939,000	$1,046,000
Salaries And Wages	$1,699,000	$14,907,000	$12,516,000	$3,660,000
Other Special Charges	-	$246,000	-	-

Fetched: 2026-06-12

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$1,828,000	$3,012,000	$-1,631,000	$28,956,000
Total Assets	$40,905,000	$38,906,000	$63,925,000	$76,384,000
Total Non Current Assets	$17,224,000	$11,802,000	$16,742,000	$24,383,000
Goodwill And Other Intangible Assets	$16,368,000	$10,449,000	$14,854,000	$21,885,000
Other Intangible Assets	$16,368,000	$10,449,000	$14,854,000	$21,885,000
Current Assets	$23,681,000	$27,104,000	$47,183,000	$52,001,000
Prepaid Assets	$201,000	$534,000	$1,528,000	$198,000
Inventory	$2,148,000	$3,145,000	$1,953,000	$0
Receivables	$456,000	$3,863,000	$708,000	$721,000
Other Receivables	$410,000	$1,387,000	$350,000	$721,000
Accounts Receivable	$46,000	$2,476,000	$358,000	$0
Cash Cash Equivalents And Short Term Investments	$20,876,000	$19,562,000	$42,994,000	$51,082,000
Cash And Cash Equivalents	$3,250,000	$10,436,000	$4,255,000	$10,587,000
Cash Equivalents	$2,618,000	$9,492,000	$1,101,000	$6,964,000
Cash Financial	$632,000	$944,000	$3,154,000	$3,623,000
Debt
Net Debt	$5,689,000	$3,001,000	$5,518,000	-
Total Debt	$10,150,000	$15,040,000	$11,591,000	$12,324,000
Long Term Debt And Capital Lease Obligation	$5,437,000	$10,039,000	$7,918,000	$10,355,000
Long Term Debt	$4,460,000	$8,958,000	$6,628,000	$8,626,000
Current Debt And Capital Lease Obligation	$4,713,000	$5,001,000	$3,673,000	$1,969,000
Current Debt	$4,479,000	$4,479,000	$3,145,000	$1,542,000
Other Current Borrowings	$4,479,000	$4,479,000	$3,145,000	$1,542,000
Liabilities
Total Liabilities Net Minority Interest	$17,560,000	$25,445,000	$50,702,000	$25,543,000
Total Non Current Liabilities Net Minority Interest	$5,437,000	$10,039,000	$7,918,000	$14,864,000
Current Liabilities	$12,123,000	$15,406,000	$42,784,000	$10,679,000
Other Current Liabilities	$2,174,000	$1,691,000	$11,932,000	-
Payables And Accrued Expenses	$4,926,000	$8,283,000	$13,803,000	$8,333,000
Payables	$4,031,000	$5,583,000	$10,957,000	$7,050,000
Other Payable	$538,000	-	$88,000	$84,000
Accounts Payable	$3,493,000	$5,583,000	$10,869,000	$6,966,000
Current Deferred Liabilities	-	$0	$12,957,000	$0
Derivative Product Liabilities	-	-	$11,932,000	$4,509,000
Equity
Common Stock Equity	$18,196,000	$13,461,000	$13,223,000	$50,841,000
Total Equity Gross Minority Interest	$23,345,000	$13,461,000	$13,223,000	$50,841,000
Stockholders Equity	$18,196,000	$13,461,000	$13,223,000	$50,841,000
Other Equity Interest	$3,686,000	$5,367,000	$1,408,000	$1,408,000
Gains Losses Not Affecting Retained Earnings	$14,500,000	$16,131,000	$15,584,000	$13,349,000
Other Equity Adjustments	$14,500,000	$16,131,000	$15,584,000	$13,349,000
Retained Earnings	$-401,002,000	$-399,827,000	$-390,606,000	$-329,992,000
Other
Ordinary Shares Number	$2,610,814,390	$1,336,670,575	$1,086,589,165	$922,958,942
Share Issued	$2,610,814,390	$1,336,670,575	$1,086,589,165	$922,958,942
Tangible Book Value	$1,828,000	$3,012,000	$-1,631,000	$28,956,000
Invested Capital	$27,135,000	$26,898,000	$22,996,000	$61,009,000
Working Capital	$11,558,000	$11,698,000	$4,399,000	$41,322,000
Capital Lease Obligations	$1,211,000	$1,603,000	$1,818,000	$2,156,000
Total Capitalization	$22,656,000	$22,419,000	$19,851,000	$59,467,000
Minority Interest	$5,149,000	$0	-	-
Additional Paid In Capital	$327,584,000	$353,693,000	$355,482,000	$338,976,000
Capital Stock	$73,428,000	$38,097,000	$31,355,000	$27,100,000
Common Stock	$73,428,000	$38,097,000	$31,355,000	$27,100,000
Long Term Capital Lease Obligation	$977,000	$1,081,000	$1,290,000	$1,729,000
Current Capital Lease Obligation	$234,000	$522,000	$528,000	$427,000
Pensionand Other Post Retirement Benefit Plans Current	$310,000	$431,000	$419,000	$377,000
Current Accrued Expenses	$895,000	$2,700,000	$2,846,000	$1,283,000
Net PPE	$856,000	$1,353,000	$1,888,000	$2,498,000
Accumulated Depreciation	$-5,102,000	$-4,979,000	$-5,540,000	$-4,782,000
Gross PPE	$5,958,000	$6,332,000	$7,428,000	$7,280,000
Leases	$3,587,000	$3,587,000	$4,133,000	$4,133,000
Other Properties	$1,571,000	$1,571,000	$1,613,000	$1,606,000
Machinery Furniture Equipment	$800,000	$1,174,000	$1,682,000	$1,541,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$17,626,000	$9,126,000	$38,739,000	$40,495,000
Current Deferred Revenue	-	$0	$12,957,000	$0
Finished Goods	-	$165,000	$579,000	$0
Work In Process	-	$2,980,000	$471,000	$0
Raw Materials	-	$0	$903,000	$0

Fetched: 2026-06-12

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-8,101,000	$-43,927,000	$-22,905,000	$-26,556,000
Operating Activities
Operating Cash Flow	$-8,074,000	$-43,873,000	$-22,608,000	$-26,240,000
Cash Flow From Continuing Operating Activities	$-8,074,000	$-43,873,000	$-22,608,000	$-26,240,000
Operating Gains Losses	$-8,244,000	$-18,349,000	$11,236,000	$-5,871,000
Investing Activities
Capital Expenditure	$-27,000	$-54,000	$-297,000	$-316,000
Investing Cash Flow	$-8,545,000	$29,374,000	$1,444,000	$4,006,000
Cash Flow From Continuing Investing Activities	$-8,545,000	$29,374,000	$1,444,000	$4,006,000
Financing Activities
Issuance Of Capital Stock	$13,894,000	$16,357,000	$14,089,000	$14,359,000
Financing Cash Flow	$8,884,000	$20,658,000	$15,056,000	$20,438,000
Cash Flow From Continuing Financing Activities	$8,884,000	$20,658,000	$15,056,000	$20,438,000
Net Common Stock Issuance	$13,894,000	$16,357,000	$14,089,000	$14,359,000
Common Stock Issuance	$13,894,000	$16,357,000	$14,089,000	$14,359,000
Other
Repayment Of Debt	$-5,010,000	$-14,944,000	$-1,988,000	$-3,052,000
Issuance Of Debt	$0	$19,223,000	$0	$9,126,000
Interest Paid Supplemental Data	$1,268,000	$10,387,000	$1,111,000	$593,000
End Cash Position	$3,250,000	$10,436,000	$4,255,000	$10,587,000
Beginning Cash Position	$10,436,000	$4,255,000	$10,587,000	$12,990,000
Effect Of Exchange Rate Changes	$549,000	$22,000	$-224,000	$-607,000
Changes In Cash	$-7,735,000	$6,159,000	$-6,108,000	$-1,796,000
Proceeds From Stock Option Exercised	$0	$22,000	$2,955,000	$5,000
Net Issuance Payments Of Debt	$-5,010,000	$4,279,000	$-1,988,000	$6,074,000
Net Short Term Debt Issuance	$-4,498,000	$-14,433,000	$-1,543,000	-
Short Term Debt Payments	$-4,498,000	$-14,433,000	$-1,543,000	-
Net Long Term Debt Issuance	$-512,000	$18,712,000	$-445,000	$6,074,000
Long Term Debt Payments	$-512,000	$-511,000	$-445,000	$-3,052,000
Long Term Debt Issuance	$0	$19,223,000	$0	$9,126,000
Net Investment Purchase And Sale	$-8,518,000	$29,428,000	$1,741,000	$4,322,000
Sale Of Investment	$28,126,000	$55,778,000	$49,329,000	$48,322,000
Purchase Of Investment	$-36,644,000	$-26,350,000	$-47,588,000	$-44,000,000
Net Intangibles Purchase And Sale	$-2,000	$-1,000	$-181,000	$-185,000
Purchase Of Intangibles	$-2,000	$-1,000	$-181,000	$-185,000
Net PPE Purchase And Sale	$-25,000	$-53,000	$-116,000	$-131,000
Purchase Of PPE	$-25,000	$-53,000	$-116,000	$-131,000
Change In Working Capital	$1,259,000	$-21,818,000	$15,199,000	$1,238,000
Change In Payables And Accrued Expense	$-3,478,000	$-5,508,000	$5,512,000	$1,888,000
Change In Prepaid Assets	$1,310,000	$-43,000	$-959,000	$-650,000
Change In Inventory	$997,000	$-1,192,000	$-1,953,000	$0
Change In Receivables	$2,430,000	$-2,118,000	$-358,000	$0
Changes In Account Receivables	$2,430,000	$-2,118,000	$-358,000	$0
Other Non Cash Items	$18,000	$-941,000	$1,163,000	$445,000
Stock Based Compensation	$396,000	$1,135,000	$2,321,000	$2,245,000
Asset Impairment Charge	$0	$1,256,000	$6,703,000	$0
Depreciation Amortization Depletion	$523,000	$4,065,000	$1,384,000	$654,000
Depreciation And Amortization	$523,000	$4,065,000	$1,384,000	$654,000
Gain Loss On Investment Securities	$-7,897,000	$-18,296,000	$11,054,000	$-6,254,000
Net Foreign Currency Exchange Gain Loss	$-372,000	$-53,000	$182,000	$383,000
Gain Loss On Sale Of PPE	$25,000	$0	$0	-
Net Income From Continuing Operations	$-2,026,000	$-9,221,000	$-60,614,000	$-24,951,000
Change In Other Working Capital	-	$-12,957,000	$12,957,000	-

Fetched: 2026-06-12